News Article | December 2, 2016
About Analytics Analytics helps in understanding customer behavior and anticipates future behaviors by getting meaningful insights from varioIndia tools and applications that are required for collecting, managing, and analyzing structured and unstructured data in an enterprise. VarioIndia extraction and Analytics tools are required to support management decisions and facilitate analysis of these databases. Business Analytics software enables enterprises to collect, extract, and analyze data to make better decisions, improve processes, and achieve the desired corporate goals. Its adoption is increasing because of the varioIndia benefits it provides such as data management, advanced reporting and analysis, knowledge discovery and decision making, performance management, and presentation and reporting. The analysts forecast the Analytics market in India to grow at a CAGR of 22.80 percent over the period 2014-2019. Covered in this Report This report covers the present scenario and the growth prospects of the Analytics market in India for the period 2015-2019. The Analytics market in India is categorized by two main segments: Software and Services. The Analytics Market in India 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the Analytics market in India and its growth prospects in the coming years. The report includes a detailed discussion of the key vendors operating in this market. Other Prominent Vendors • Accenture • Absolutdata • Adnear • Affine Analytics • Blueocean Market Intelligence • BDI Systems • BRIDGEi2i • Citibank • Dataweave • Dell • eClerx • Evalueserve • EXL • Fintellix • Flutura • Formcept • Fractal Analytics • Germin8 • Gramener • HSBC • IdealAnalytics • Indix Corp. • InRev systems • JP Morgan Chase • Knowledge Foundry • LatentView • Marketelligent • Mckinsey & Company • Nanobi Data Analytics • NettPositive • Nuevera • Opera Solutions • Qubole • Sapience • Serco • Veda Semantics • Wipro • WNS • ZS Associates Key Market Driver • Need to Improve Efficiency and Reduce Operational Costs • For a full, detailed list, view our report Key Market Trend • Emergence of Open Source • For a full, detailed list, view our report Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? 06. Market Landscape 06.1 Market Overview 06.2 Market Size and Forecast 06.3 Evolution of Analytics 06.4 Scope of Predictive Analytics 06.5 New Analytics Jobs in India by Industry 2015 06.6 Three Distinct Features about Indian Analytics Market 06.7 Five Forces Analysis 07. Market Segmentation by Category 07.1 Analytics Software Market in India 07.1.1 Market Size and Forecast 07.2 Analytics Services Market in India 07.2.1 Market Size and Forecast Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
News Article | December 9, 2016
— This report studies the global Application Outsourcing in Banking Sector market, analyzes and researches the Application Outsourcing in Banking Sector development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like IBM Optimization Group Infinit Outsourcing McKinsey Accenture Fair Issac Mu sigma Analyx Genpact Capgemini Fractal Analytics TCS Wipro ZS Associates Cogneesol For more information or any query mail at firstname.lastname@example.org Market segment by Application, Application Outsourcing in Banking Sector can be split into Application 1 Application 2 Application 3 United States, EU, Japan, China, India and Southeast Asia Application Outsourcing in Banking Sector Market Size, Status and Forecast 2021 1 Industry Overview of Application Outsourcing in Banking Sector 1.1 Application Outsourcing in Banking Sector Market Overview 1.1.1 Application Outsourcing in Banking Sector Product Scope 1.1.2 Market Status and Outlook 1.2 Global Application Outsourcing in Banking Sector Market Size and Analysis by Regions 1.2.1 United States 1.2.2 EU 1.2.3 Japan 1.2.4 China 1.2.5 India 1.2.6 Southeast Asia 1.3 Application Outsourcing in Banking Sector Market by End Users/Application 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 2 Global Application Outsourcing in Banking Sector Competition Analysis by Players 2.1 Application Outsourcing in Banking Sector Market Size (Value) by Players (2015-2016) 2.2 Competitive Status and Trend 2.2.1 Market Concentration Rate 2.2.2 Product/Service Differences 2.2.3 New Entrants 2.2.4 The Technology Trends in Future 3 Company (Top Players) Profiles 3.1 IBM 3.1.1 Company Profile 3.1.2 Main Business/Business Overview 3.1.3 Products, Services and Solutions 3.1.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.1.5 Recent Developments 3.2 Optimization Group 3.2.1 Company Profile 3.2.2 Main Business/Business Overview 3.2.3 Products, Services and Solutions 3.2.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.2.5 Recent Developments 3.3 Infinit Outsourcing 3.3.1 Company Profile 3.3.2 Main Business/Business Overview 3.3.3 Products, Services and Solutions 3.3.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.3.5 Recent Developments 3.4 McKinsey 3.4.1 Company Profile 3.4.2 Main Business/Business Overview 3.4.3 Products, Services and Solutions 3.4.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.4.5 Recent Developments 3.5 Accenture 3.5.1 Company Profile 3.5.2 Main Business/Business Overview 3.5.3 Products, Services and Solutions 3.5.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.5.5 Recent Developments 3.6 Fair Issac 3.6.1 Company Profile 3.6.2 Main Business/Business Overview 3.6.3 Products, Services and Solutions 3.6.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.6.5 Recent Developments 3.7 Mu sigma 3.7.1 Company Profile 3.7.2 Main Business/Business Overview 3.7.3 Products, Services and Solutions 3.7.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.7.5 Recent Developments 3.8 Analyx 3.8.1 Company Profile 3.8.2 Main Business/Business Overview 3.8.3 Products, Services and Solutions 3.8.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.8.5 Recent Developments 3.9 Genpact 3.9.1 Company Profile 3.9.2 Main Business/Business Overview 3.9.3 Products, Services and Solutions 3.9.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.9.5 Recent Developments 3.10 Capgemini 3.10.1 Company Profile 3.10.2 Main Business/Business Overview 3.10.3 Products, Services and Solutions 3.10.4 Application Outsourcing in Banking Sector Revenue (Value) (2011-2016) 3.10.5 Recent Developments 3.11 Fractal Analytics 3.12 TCS 3.13 Wipro 3.14 ZS Associates 3.15 Cogneesol For more information or any query mail at email@example.com ABOUT US: Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories. For more information, please visit https://www.wiseguyreports.com
News Article | February 28, 2017
Several big drugmakers are trying to quell the furor over high drug prices by revealing more information about their pricing and even pledging to keep a lid on increases. No one should expect to be paying less for medicine anytime soon, experts say, though the drugmakers' response to public pressure may help slow the rise in prices for some drugs. The latest drugmaker move came Monday, when Johnson & Johnson, the world's biggest maker of health care products, issued its first public report on price increases for its drugs. The political and public anger over drug prices has been stirred by a few factors: Sky-high prices for new drugs, enormous increases for many existing drugs, and changes in insurance coverage that make patients pay a bigger portion of the drug bill. The drug industry's top two lobbying groups have been running advertising campaigns that reinforce a point the industry has long pushed: Medical breakthroughs that improve or save patients' lives are very difficult - and expensive - and high prices are needed to fund research into new treatments. But now individual companies are making their own cases to the public in hopes of showing that at least they aren't as bad as some other guys. Erik Gordon, a professor and pharmaceuticals analyst at University of Michigan's Ross School of Business said those drugmakers promising to hold future price hikes below 10 percent will be able to lock in substantial increases but still say they kept their pledge. "If it works, it's brilliant," he says. "They're doing everything but the obvious, simple thing - just lower the price." On Monday, Johnson & Johnson reported that over the past five years, the list price, or retail price, of its drugs rose less than 10 percent each year on average, while the net price, the payment it receives after discounts and fees insurers and other middlemen get, rose 5 percent or less per year. That's far less than some of the eye-popping price increases that have been criticized over the past year, like the 547 percent jump over 9 years in the price of the EpiPen emergency allergy auto-injectors. But J&J's increase is still more than double the U.S. rate of inflation, which means its prices rose far faster than prices for other goods and services. Johnson & Johnson's disclosure is the latest in a string of similar moves. Sanofi SA, maker of top-selling insulin Lantus, reported earlier this month that last year its list prices increased by 2.3 percent on average, but its average net price dipped 0.5 percent because insurers got discounts that averaged 50 percent. Merck & Co. in January reported its annual net price increase since 2010 has ranged from 3.4 percent to 6.2 percent, roughly half its list price increases, while its average discount to payers climbed to 41 percent in 2016. Allergan CEO Brent Saunders kicked off the trend last fall when he announced the Botox maker had ended big list price hikes and would stick to single-digit increases. Novo Nordisk and AbbVie Inc. later followed suit. Other companies, including GlaxoSmithKline and Takeda Pharmaceuticals, say they've been keeping annual list price increases below 10 percent, though they're not making pledges. And Eli Lilly is reducing prices for most of its insulins up to 40 percent for people who pay the full price. These moves might translate to smaller price increases, according to Edward Jones analyst Ashtyn Evans. "I think in the near term, we are certainly going to see smaller price increases. We've already seen that this year," she says. "But it's possible that if the headlines die down and the government doesn't take action, that they could creep back up again." Frustration over high drug prices isn't new, but the latest uproar, the result of a series of extraordinary price hikes at a time when patients are paying substantially more for health care, has lasted far longer than in the past. Big pharmaceutical companies posted a net profit margin of nearly 26 percent last year, compared with the 10 percent average profit for the biggest 500 U.S. companies, according to FactSet. Ed Schoonveld, a former pricing director at three drugmakers and now a managing partner at consultants ZS Associates, predicts "most companies will probably jump on board" because the industry wants to escape the pricing uproar. Not everyone, though. Pfizer Inc., the biggest U.S. drugmaker, says there's no need for such pledges. Like the industry trade groups, it blames the furor on a handful of "irresponsible" companies that raised prices many times over for older products, the way Turing Pharmaceuticals, Valeant Pharmaceuticals International Inc. and EpiPen maker Mylan NV have done. Schoonveld said no matter what pledges companies make, overall drug spending will continue to rise as costly new therapies emerge and the population ages. And high prices will continue to shock the public: Earlier this month Marathon Pharmaceuticals LLC triggered a huge backlash by announcing it would charge $89,000 a year for its muscular dystrophy drug Emflaza, an old steroid that some patients had been importing from other countries for roughly $1,000 per year. Marathon has since delayed Emflaza's launch while it talks with patients and advocacy groups about ensuring access to the drug.
News Article | February 28, 2017
A recent forecast by Cisco VNI predicts that internet video will account for 79% of all global internet traffic by 2020—up from 63% in 2015. The report also forecasts that video will increase fourfold between 2015 and 2020, with video traffic ultimately accounting for 82% of consumer internet traffic and 66% of business internet traffic.* The growing trend of web video watching has also impacted the healthcare industry, influencing how physicians now access medical information. Before work, at the point of care, in between patient visits, and after work, HCPs are spending an average of 11 hours online per week.** In fact, 71% of U.S. physicians are now watching video online, which has become the preferred way to access new medical information and topical research. However, given the restrictions on physicians’ time, it is not surprising that 60% who watch professional videos online will only watch a video up to 6 minutes in length.*** Viscira, a leading provider of digital marketing solutions and software products for the life sciences industry, has capitalized on the increased viewing of online videos by healthcare providers (HCPs) by offering its life sciences clients an enhanced, broadcast-quality video solution for peer-to-peer education and other applications. This on-demand video program delivers a visually stunning combination of high-definition video content, sophisticated 2D and 3D imagery, dynamic motion graphics, and other creative elements to maximize visual impact and increase the effectiveness of messaging with target audiences. The video solution can be optimized and formatted for multiple media channels and devices, including the web, broadcast, congresses, and various mobile devices such as the Apple® iPhone® and iPad®. This KOL video module is just one of Viscira’s many Vilumina™ video solutions, which also include live-action videos, documentary-style videos, patient and caregiver testimonials, product demonstration videos, and other formats. “We recognize the growing trend among HCPs to access medical information via online video,” explains Marlon McKenney, Director of Video and Motion Graphics at Viscira. “Our Vilumina video solutions leverage innovative creative with state-of-the- technologies to provide our clients with powerful tools for delivering important scientific and educational messages to their target audiences.” Viscira’s video capabilities sit at the intersection of Hollywood and life science, enabling high-impact message delivery and audience retention. In fact, many of Viscira’s video production team members had worked in the broadcast and film industry before coming to the company. All of Viscira’s video work is executed in-house. In addition to the Viscira’s Vilumina video solutions, the company also offers a streamlined, lower-cost video product called VisciCast™ for clients with more limited budgets and simpler delivery needs. To schedule a demonstration of Viscira’s video solutions, please contact the company at 415-848-8010, or email sales(at)viscira.com. About Viscira Viscira is dedicated to the design and development of digital marketing solutions and interactive software applications for the life sciences industry. Viscira provides a suite of programs that integrate best-in-class technology to deliver engaging and memorable content via various electronic channels. Viscira is part of the Sudler & Hennessey Group, a leading global healthcare communications network. For more information, please visit the company’s website at http://www.viscira.com, or contact Noёl Ashekian at (617) 429-0834. *Cisco Visual Networking Index (VNI) Complete Forecast for 2015 to 2020 http://www.cisco.com/c/en/us/solutions/service-provider/visual-networking-index-vni/index.html **2013 ZS Associates 11-18-13 v1.1 ***Manhattan Research, Taking the Pulse® U.S. 2015 Apple, iPhone, and iPad are trademarks of Apple Inc., registered in the U.S. and other countries.
Khandelwal S.,ZS Associates |
Mathias A.,ZS Associates
Journal of Medical Marketing | Year: 2011
The pharmaceutical industry is faced with a challenging business environment, a changing marketplace, and evolving customer landscape. Sales and marketing are developing new novel methods to segment customers, and develop sales and marketing strategies to improve sales and profitability. A 360° view of customers built by integrating multiple data sources can serve as a foundation for effective segmentation which can aid marketing and sales strategy and tactics to better target and win customers, and drive sales and profits. A 360° view of customers brings traditionally disconnected dimensions or attributes of customers together in a way that allows marketers to create segments based on seemingly unrelated aspects and develop unique insights. © The Author(s) 2011.
Chressanthis G.A.,Temple University |
Khedkar P.,ZS Associates |
Jain N.,ZS Associates |
Poddar P.,ZS Associates |
Journal of Clinical Hypertension | Year: 2012
The authors explored to what extent important medical decisions by practitioners can be influenced by pharmaceutical representatives and, in particular, whether restricting such access could delay appropriate changes in clinical practice. Medical practices were divided into four categories based on the degree of sales representative access to clinicians: very low, low, medium, and high from a database compiled by ZS Associates called AccessMonitor (Evanston, IL) used extensively by many pharmaceutical companies. Clinical decisions of 58,647 to 72,114 physicians were statistically analyzed using prescription data from IMS Health (Danbury, CT) in three critical areas: an innovative drug for type 2 diabetes (sitagliptin), an older diabetes drug with a new Food and Drug Administration-required black box warning for cardiovascular safety (rosiglitazone), and a combination lipid therapy that had reported negative outcomes in a clinical trial (simvastatin+ezetimbe). For the uptake of the new diabetes agent, the authors found that physicians with very low access to representatives had the lowest adoption of this new therapy and took 1.4 and 4.6 times longer to adopt than physicians in the low- and medium-access restriction categories, respectively. In responding to the black box warning for rosiglitazone, the authors found that physicians with very low access were4.0 times slower to reduce their use of this treatment than those with low access. Likewise, there was significantly less response in terms of changing prescribing to the negative news with the lipid therapy for physicians in more access-restricted offices. Overall, cardiologists were the most responsive to information changes relative to primary care physicians. These findings emphasize that limiting access to pharmaceutical representatives can have the unintended effect of reducing appropriate responses to negative information about drugs just as much as responses to positive information about innovative drugs. © 2012 Wiley Periodicals, Inc.
Apger J.,East Carolina University |
Reubens M.,East Carolina University |
Henderson L.,East Carolina University |
Gouge C.A.,East Carolina University |
And 3 more authors.
Genetics | Year: 2010
DNA replication and the correct packaging of DNA into different states of chromatin are both essential processes in all eukaryotic cells. High-fidelity replication of DNA is essential for the transmission of genetic material to cells. Likewise the maintenance of the epigenetic chromatin states is essential to the faithful reproduction of the transcriptional state of the cell. It is becoming more apparent that these two processes are linked through interactions between DNA replication proteins and chromatin-associated proteins. In addition, more proteins are being discovered that have dual roles in both DNA replication and the maintenance of epigenetic states. We present an analysis of two Drosophila mutants in the conserved DNA replication protein Mcm10. A hypomorphic mutant demonstrates that Mcm10 has a role in heterochromatic silencing and chromosome condensation, while the analysis of a novel C-terminal truncation allele of Mcm10 suggests that an interaction with Mcm2 is not required for chromosome condensation and heterochromatic silencing but is important for DNA replication. Copyright © 2010 by the Genetics Society of America.
Bhattacharya B.,Indian Institute of Technology Kharagpur |
Chatterjee A.,Virginia Polytechnic Institute and State University |
Agrawal G.,ZS Associates |
Mondal A.,Nuclear Power Corporation of India
Nuclear Engineering and Design | Year: 2013
Partial safety factors (PSFs) used in reliability-based design are intended to account for uncertainties in load, material and mathematical modeling while ensuring that the target reliability is satisfied for the relevant class of structural components in the given load combination and limit state. This paper describes the methodology in detail for developing a set of optimal reliability-based PSFs for the design of prestressed concrete inner containment shells in Indian NPPs under Main Steam Line Break (MSLB)/Loss of Coolant Accident (LOCA) conditions at two performance levels in flexure: cracking and collapse. The methodology follows current design practices in the country, accounts for uncertainties in loads and material properties and dependence among capacities and demands, develops the limit states from first principles, explicitly lays down the target reliabilities and criteria for PSF optimization. The optimization of the PSFs is based on reliability indices for each representative group of components obtained from importance sampling and a local linear response surface fit. A detailed numerical example on a typical 220 MWe Indian PHWR demonstrating the methodology is provided. © 2013 Elsevier B.V.
Mathias A.,ZS Associates
Journal of Medical Marketing | Year: 2011
The FDA has mandated Risk Evaluation and Mitigation Strategy programs to manage risks associated with drugs. REMS programs comprise elements to assure safe use (ETASUs), and companies need to implement some (least restrictive) to all ETASUs (most restrictive) required by the FDA . Implementing ETASUs can require companies to perform a number of different activities from better educating customers and end-users to continuous monitoring of customers and end-users for risk of adverse events. In performing activities required for ETASUs, companies need to acquire, create and manage signifi cant amounts of data on their customers, end-users, product use, distribution and so on. If effectively done, these data can be married with other data from customer relationship management, marketing campaigns and so on to create a business intelligence goldmine to support and enhance marketing and sales effectiveness, and business operations. © SAGE Publications, 2011.
News Article | November 21, 2016
Customer relationship management (CRM) revenues grew 12.3% to $26.3 billion from 2014 to 2016, according to Gartner, the world’s leading information technology research and advisory company. This upward trajectory is not likely to change anytime soon, as accurate CRM data has infinite benefits to organizations of all sizes. Accurate data closes a significant gap between what sales is doing and what executives are seeing.1 CRM refers to practices, strategies and technologies that companies use to manage and analyze customer interactions and data throughout the customer lifecycle.2 The goal is to improve business relationships with customers, assist in customer retention and drive sales growth. Asad Khan, Founder of ePlanet Communications Inc, a global business process outsourcing provider, points out the sad reality that only a very small amount of most firms’ CRM data is accurate. According to consulting firm ZS Associates, 74% of respondents say improving the quality of their data is a top priority, and overall fewer than one in four respondents believe that their company’s data is accurate. The risk of relying on inaccurate data is incalculable. Aside from the fact that sales teams won’t have the appropriate information needed to “always be closing,” lack of accurate data leads to enormous issues of mistrust between a rep and the technology they’re provided, resulting in an overall lack of adoption. Given the size of the investment in CRM, this is a problem that needs to be solved unless a business wants to forfeit up to hundreds of thousands of dollars a year. “CRM has become one of the most influential factors in building brand loyalty and strengthening brand image,” Khan observed. “Call center interaction in CRM is often cited in defining customer service; however, there are many facets of CRM outsourcing that have evolved with rising customer needs and expectations.” Khan also noted that smaller businesses may find that outsourcing their CRM is a much more cost-effective approach. In 2008, just 12% of businesses using CRM stored their software in the cloud, but this figure had risen to 87% by 2015.3 And the global CRM outsourcing market was projected to grow at a compound annual gross rate (CAGR) of 5.75% over the period 2014 to 2019.4 The cost-effectiveness of outsourcing capital and labor-intensive operations is one of the major factors driving the growth of the market, per a Research and Markets’ CRM report. More companies are outsourcing the back-office functions that require more infrastructure, capital investments and HR training, thus reducing their cost of operations. CRM systems are designed to compile information on customers across different channels, i.e., points of contact between the customer and the company. These could include the company’s website, telephone, live chat, direct mail, marketing materials and social media. CRM systems can also give customer-facing staff detailed information on customers’ personal information, purchase history, buying preferences and concerns. Khan emphasized, “The combination of our comprehensive contact centers, highly professional staff and data-intensive CRM capability that provides accurate CRM data, pays off for our client companies by facilitating growth, helping them create jobs and improving their bottom line.” ePlanet Communication is a global business process outsourcing provider with extensive experience in call center operations, digital media solutions, and direct response solutions. By using its integrated channel management capabilities and highly-trained staff, ePlanet develops and deploys inbound and outbound customer support fully integrated with its clients’ marketing campaigns. Digital media solutions include website design, digital franchising, fully functioning eCommerce operations, and the creation of interactive, immersive and responsive social media campaigns across different platforms. ePlanet is also highly experienced in the area of direct response trial, consistently delivering improved customer satisfaction, increased customer retention, and better order value. To learn more about ePlanet and its capabilities, please visit http://www.eplanetcom.com. 1. N.p., n.d. Web. cmswire.com/customer experience “What Next-gen CRM Will Look Like: The Coming Accuracy Wave”. 3. N.p., 20 Oct. 2016. Web. @BetaNews. “What You Need to Know About CRM.”